eiaab home > paper Center > paper list.
Enter your KeyWord (Ex. ELISA Kit, Cuticular Active Peptide Factor, etc)
search
Search content in EIAab's paper.

花生过敏小鼠腹腔肥大细胞 SOC 活性与 ROS 相关性研究

Posted by 杨成彬, 闫浩, 刘晓宇,et al. on 2014-04-23 19:33:23

摘要: 研究花生过敏状态下的 C57BL/6 小鼠腹腔肥大细胞的激活与钙离子通道之间的内在联系,  以及探讨肥大细胞钙离子通道与 ROS(reactive oxygen species)之间的关系. 18 只雌性 C57BL/6 小鼠随机分为 PBS 组(A组)、花生过敏模型组(B 组)、vitamin A 和 vitamin E 灌胃治疗组(C 组).  酶联免疫吸附实验检测各组腹腔上清液中特异性的 IgE 和 IgG2a 水平,  以及细胞因子的变化,  另外测定腹腔上清液与血清中的组胺、ROS 含量.  腹腔灌洗液中细胞涂片,  进行肥大细胞计数和脱颗粒比例统计,  荧光共聚焦显微镜观察腹腔肥大细胞钙离子通道 SOC(Store oprated channel)的活性.  腹腔上清液中花生特异性 IgE、IL-4、IL-10、组胺、ROS、血清中的组胺和 ROS、腹腔灌洗液中肥大细胞总数、肥大细胞脱颗粒比例,  都呈现出 A 组<C 组<B 组的趋势.  腹腔上清液中 IgG2a、1L-6、IL-10 的水平 B 组低于 A 组,  但高于 C 组.  共聚焦显微镜观察肥大细胞内部钙离子荧光强度数据表明 B 组小鼠腹腔肥大细胞 SOC 通道有更强的生理活性,  而 C 组肥大细胞 SOC 通道被抑制,  表明 ROS 的水平与肥大细胞 ROS 活性是正相关.  花生过敏组肥大细胞 SOC 较 PBS 组活性更高,抗氧化剂药物可能通过清除 ROS 来抑制肥大细胞 SOC 通道的活性,  进而抑制肥大细胞脱颗粒,  缓解过敏症状.  这为进一步研究抗氧化剂治疗花生过敏反应的机理奠定了基础,  同时对临床治疗过敏反应也有一定的指导意义.

IL-27 在多发性骨髓瘤患者及骨髓瘤细胞系中的表达

Posted by 夏天, 李建平, 李文倩, et al. on 2014-04-23 19:22:05

Bone Structure and Strength are Enhanced in Rats Programmed by Early Overfeeding

Posted by L de Albuquerque Maia, PC Lisboa, E de Oliveira, et al. on 2014-04-23 19:12:58

 

Abstract (provisional)

Introduction

Different mesenchymal stromal cells (MSC) have been successfully isolated and expanded in vitro and nowadays they are tested in clinical trials for a wide variety of diseases. Whether all MSC express the same cell surface markers or have a similar secretion profile is still controversial, making it difficult to decide which stromal cell may be better for a particular application.

Methods

We isolated human mesenchymal stromal cells from bone marrow (BM), adipose tissue (AT) and Wharton's jelly (WJ) and cultured them in fetal bovine serum supplemented media. We evaluated proliferation, in vitro differentiation (osteogenic, adipogenic and chondrogenic potential), expression of cell surface markers and protein secretion using Luminex and ELISA assays.

Results

Cell proliferation was higher for WJ-MSC, followed by AT-MSC. Differences in surface expression markers were observed only for CD54 and CD146. WJ-MSC secreted higher concentrations of chemokines, pro-inflammatory proteins and growth factors. AT-MSC showed a better pro-angiogenic profile and secreted higher amounts of extracellular matrix components and metalloproteinases.

Conclusions

Mesenchymal stromal cells purified from different tissues have different angiogenic, inflammatory and matrix remodeling potential properties. These abilities should be further characterized in order to choose the best protocols for their therapeutic use.

Phosphodiesterase-5 inhibition attenuates early renal

Posted by ON Heyman, Z Abassi, B Bishara, et al. on 2014-04-23 18:56:39

Abstract:

Acute kidney injury (AKI) is a common clinical problem that still lacks effective treatment. Phosphodiesterase-5 (PDE5) inhibitors possess anti-apoptotic and antioxidant properties, making it a promising therapy for ischemiareperfusion (I/R) injury of various organs. The present study evaluated the early nephroprotective effects of Tadala?l, a PDE5 inhibitor, in an experimental model of renal I/R. Sprague-Dawley rats were divided into two groups: vehicle-treated I/R (n  10), and Tadala?l (10 mg/kg po)-treated I/R group (n  11). After removal of the right kidney and collection of two baseline urine samples, the left renal artery was clamped for 45 min followed by reperfusion for 60, 120, 180, and 240
min. Functional and histological parameters of the kidneys from the various groups were determined. In the vehicle-treated I/R group, glomerular ?ltration rate was signi?cantly reduced compared with that in normal kidneys. In addition, the ischemic kidney showed remarkable cast formation, necrosis, and congestion, a consistent pattern of nacute tubular necrosis. Furthermore, urinary excretion of NGAL and KIM-1, two novel biomarkers of kidney injury, substantially increased following I/R insult. In contrast, Tadala?l treatment resulted in a signi?cant improvement in kidney function and amelioration of the adverse histological alterations of the ischemic kidney. Noteworthy, the urinary excretion of NGAL and KIM-1 markedly decreased in the Tadala?l-treated I/R group. These ?ndings demonstrate that Tadala?l possesses early nephroprotective effects in rat kidneys subjected to I/R insult. This approach may suggest a prophylactic therapy for patients with ischemic AKI.

Page 1 of 86